MEDI-546

DRUG3 trials

Sponsors

MedImmune LLC, AstraZeneca

Conditions

SclerodermaSystemic Lupus Erythematosus

Phase 1

A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma

CompletedNCT00930683

MedImmune LLCScleroderma

Start: 2009-09-30End: 2011-07-31Updated: 2012-05-08

Phase 2

Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.

CompletedNCT01559090

AstraZenecaSystemic Lupus Erythematosus

Start: 2012-04-20End: 2017-02-21Updated: 2019-03-13

Phase 3

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

Active, not recruitingNCT04877691

AstraZenecaSystemic Lupus Erythematosus

Start: 2021-06-08End: 2026-11-06Updated: 2026-07-27

Related Papers

Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study.

2014-02-2476 citations